Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-5277.55%
operating margin TTM
-5938.96%
revenue TTM
203.30 Thousand
revenue per share TTM
0.01$
valuation ratios | |
|---|---|
| pe ratio | -3.03 |
| peg ratio | -0.84 |
| price to book ratio | 0.99 |
| price to sales ratio | 160.76 |
| enterprise value multiple | -5.97 |
| price fair value | 0.99 |
profitability ratios | |
|---|---|
| gross profit margin | 83.58% |
| operating profit margin | -5938.96% |
| pretax profit margin | -5269.1% |
| net profit margin | -5277.55% |
| return on assets | -30.42% |
| return on equity | -37.86% |
| return on capital employed | -35.83% |
liquidity ratio | |
|---|---|
| current ratio | 21.45 |
| quick ratio | 21.45 |
| cash ratio | 20.40 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 458.15 |
| days of payables outstanding | 2,881.18 |
| cash conversion cycle | -2,423.03 |
| receivables turnover | 0.80 |
| payables turnover | 0.13 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.03 |
| debt equity ratio | 0.03 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -8.53 |
cash flow ratios | |
|---|---|
| free cash flow per share | -4.04 |
| cash per share | 13.88 |
| operating cash flow per share | -3.99 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -8.53 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -83.31 |
Frequently Asked Questions
When was the last time Keros Therapeutics, Inc. (NASDAQ:KROS) reported earnings?
Keros Therapeutics, Inc. (KROS) published its most recent earnings results on 06-11-2024.
What is Keros Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Keros Therapeutics, Inc. (NASDAQ:KROS)'s trailing twelve months ROE is -37.86%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Keros Therapeutics, Inc. (KROS) currently has a ROA of -30.42%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did KROS's net profit margin stand at?
KROS reported a profit margin of -5277.55% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is KROS's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 21.45 in the most recent quarter. The quick ratio stood at 21.45, with a Debt/Eq ratio of 0.03.